Isoray - Innovative Brachytherapy

Medpage Today: “EBRT with Brachytherapy Matches Surgery for Prostate Ca”

Worse survival without [brachytherapy] boost in high-risk patients

Ronald D. Ennis, MD. Image credit: OncLive.

At long last, the mounting scientific evidence for the value of brachytherapy for prostate cancer treatment is starting to generate more awareness among the care community and associated industry publications.

Responding to a recent report in the Journal of Clinical Oncology, Charles Bankhead, Senior Associate Editor for Medpage Today published the following:

Men who had EBRT plus ADT, but no brachytherapy, had a significantly greater mortality risk versus surgery, reported Ronald D. Ennis, MD, of Rutgers Cancer Institute of New Jersey in New Brunswick, and colleagues in the Journal of Clinical Oncology.

“In the absence of randomized trials, these data, in conjunction with patient-reported quality of life, should be shared with patients to help guide their individualized treatment decisions,” they added.

“I think we’re starting to see that radical prostatectomy isn’t offering much of an advantage over a radiation therapy approach,” [Jeff] Michalski, MD of Washington University in St. Louis told MedPage Today. “The caveats are that these aren’t prospective studies looking at these high-risk groups of patients, and there are subtle selection differences that we may never be able to control outside the context of a randomized study.”

Brachytherapy’s place in high-risk disease

“I do believe that men with high-risk disease need not undergo radical prostatectomy,” said Michalski, who was not involved in the study. “They need to meet with a radiation oncologist to compare the pros and cons of treatment with a combination of external beam radiation therapy and hormone therapy and, when appropriate, brachytherapy, because that does appear to offer some benefit.”

Read the data-driven article in its entirety here.

Given the advancements in imaging, delivery systems and a new, fast acting, short half-life isotope (Cesium-131), it is time for those treating prostate cancer to take another look at brachytherapy. To arrange a call or meeting contact customerservice@isoray.com

It’s the Details That Make Cesium-131 The Better Choice

It’s the Details That Make Cesium-131 The Better Choice

By Peter T. Heiberger, M.S. DABR, RSOLead Medical Physicist, Radiation Oncology, Aurora Health Care, Green Bay, WI When I think about Cesium-131 an old expression comes to mind. “It's the little details that are vital. Little things make big things happen.” When it...

read more
Lessons Learned About Cesium-131

Lessons Learned About Cesium-131

By Brian J. Moran, M.D. FABSMedical Director, Prostate Cancer Foundation of Chicago I am a radiation oncologist who, like many of you, has always looked for opportunities to do more for those I treat. That is how I first learned about Cesium-131 brachytherapy. In the...

read more
It’s More Than Just One Month

It’s More Than Just One Month

By CEO Lori Woods Prostate Cancer Awareness Month carries more than the obvious meaning. Of course, its intent is to raise awareness in hopes that we will motivate more men to get screened because we know all too well how that can impact lives. For us, it is also an...

read more